This inventor holds 5 USPTO granted patents and 4 published patent applications and 4 EPO patents. Top assignees: Qyuns Therapeutics Co., Ltd., Qyuns Therapeutics Co., Ltd., Jiangsu Qyuns Therapeutics Co., Ltd.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
2 out of 4 
1 out of 1 Years Active: 2024-2026
Title: Yong Kong: Innovator in Monoclonal Antibody Development
Introduction
Yong Kong is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of monoclonal antibodies. With a total of 5 patents, he has made strides in developing therapeutic solutions for various diseases.
Latest Patents
Yong Kong's latest patents include groundbreaking work on monoclonal antibodies. One of his notable inventions is the anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody, which has a high affinity for human TSLP and exhibits neutralizing activity. This antibody can be utilized for preventing or treating diseases mediated by TSLP. Another significant patent is the anti-human interleukin-33 monoclonal antibody, which also demonstrates high affinity and neutralizing activity, making it a potential treatment for diseases related to human interleukin-33.
Career Highlights
Throughout his career, Yong Kong has worked with esteemed organizations such as Qyuns Therapeutics Co., Ltd. and Jiangsu Qyuns Therapeutics Co., Ltd. His work in these companies has been instrumental in advancing research and development in therapeutic antibodies.
Collaborations
Yong Kong has collaborated with notable colleagues, including Jiwan Qiu and Wei Chen, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Yong Kong's contributions to the field of monoclonal antibodies highlight his role as a key innovator in medical research. His patents reflect a commitment to developing effective treatments for complex diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile